Articles From: CytoSorbents Awarded $203K Phase I SBIR Contract from NHLBI/NIH for HemoDefend(TM) to CytRx to Hold Conference Call December 11, 2013 at 10:30 a.m. Eastern Time to Discuss Results of Global Phase 2b Clinical Trial with Aldoxorubicin versus Doxorubicin as First-Line Therapy in Advanced Soft Tissue Sarcomas


http://media.marketwire.com/attachments/201309/65809_CytoSorbentsLogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1049174&ProfileId=051205&sourceType=1 MONMOUTH JUNCTION, NJ --
Sign-up for CytoSorbents Awarded $203K Phase I SBIR Contract from NHLBI/NIH for HemoDefend(TM) investment picks
2014/3/7
MONMOUTH JUNCTION, N.J. , March 7, 2014 /PRNewswire/ -- CytoSorbents Corporation (OTCBB: CTSO) , a Nevada corporation, today announced that it has entered into subscription agreements with certain institutional investors to sell approximately $10,200,000 of its common stock and warrants to purchase common stock in a registered direct offering.
Sign-up for CytoSorbents Corporation Announces $10,200,000 Registered Direct Offering investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1044704&ProfileId=051205&sourceType=1 MONMOUTH JUNCTION, NJ --
Sign-up for CytoSorbents Expands CytoSorb(R) Dosing Study to Eight Clinical Trial Sites investment picks
2013/12/16
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1076432&ProfileId=051205&sourceType=1 MONMOUTH JUNCTION, NJ --
Sign-up for CytoSorbents Reports on Successful DIVI 2013 Conference investment picks
http://media.marketwire.com/attachments/201401/70080_cytosorbents.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1079794&ProfileId=051205&sourceType=1 MONMOUTH JUNCTION, NJ --
Sign-up for CytoSorbents to Exhibit at the 43rd Society of Critical Care Medicine Congress and Present at the Biotech Showcase 2014 investment picks
2013/8/28
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1046219&ProfileId=051205&sourceType=1 MONMOUTH JUNCTION, NJ --
Sign-up for CytoSorbents to Present at the Rodman & Renshaw Annual Global Investment Conference investment picks
2013/10/15
CytRx Corporation (Nasdaq: CYTR) , a biopharmaceutical research and development company specializing in oncology, today announced the closing of its previously announced underwritten public offering.
Sign-up for CytRx Announces Closing of Public Offering of Common Stock investment picks
2014/2/5
CytRx Corporation (Nasdaq: CYTR) , a biopharmaceutical research and development company specializing in oncology, today announced the closing of its previously announced underwritten public offering.
Sign-up for CytRx Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares investment picks
2013/10/11
CytRx Corporation (Nasdaq: CYTR) , a biopharmaceutical research and development company specializing in oncology, today announced the sale of an additional 1.5 million shares of common stock pursuant to the exercise in full by the underwriters of the over-allotment option granted to the underwriters in connection with CytRx's recently announced public offering of 10.0 million shares of common stock at a price to the public of $2.25 per share.
Sign-up for CytRx Announces Exercise of Underwriters’ Over-Allotment Option investment picks
2014/1/31
CytRx Corporation (Nasdaq: CYTR) , a biopharmaceutical research and development company specializing in oncology, today announced the pricing of its previously announced underwritten public offering.
Sign-up for CytRx Announces Pricing of Approximately $75 Million Public Offering of Common Stock investment picks
CytRx Corporation (Nasdaq: CYTR) , a biopharmaceutical research and development company specializing in oncology, today announced its intention, subject to market and other conditions, to commence a public offering of its common stock.
Sign-up for CytRx Announces Proposed Public Offering of Common Stock investment picks
2014/1/30
CytRx Corporation (Nasdaq: CYTR) , a biopharmaceutical research and development company specializing in oncology, today announced its intention, subject to market and other conditions, to commence an underwritten public offering of its common stock.
Sign-up for CytRx Announces Proposed Public Offering of Common Stock investment picks
2014/4/10
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that the Company will host a Research and Development Day on Friday, May 2, from 8:30 – 11:30 am EDT at the Harvard Club in New York City.
Sign-up for CytRx Announces Research and Development Day and Webcast investment picks
2014/1/16
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the appointment of Shanta Chawla, M.D. as Vice President, Clinical Development.
Sign-up for CytRx Appoints Shanta Chawla, M.D. as Vice President, Clinical Development investment picks
2014/1/14
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that the first patient has been dosed in the Company’s Phase 2 clinical trial with aldoxorubicin for the treatment of unresectable glioblastoma multiforme (GBM), a deadly form of brain cancer.
Sign-up for CytRx Corporation Doses First Patient in Phase 2 Clinical Trial with Aldoxorubicin for the Treatment of Unresectable Glioblastoma Multiforme (Brain Cancer) investment picks
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that President and CEO Steven A.
Sign-up for CytRx Corporation to Present at the Oppenheimer 24th Annual Healthcare Conference on Wednesday, December 11th, 2013 investment picks
2014/3/17
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the appointment of Felix Kratz, Ph.D. as Vice President of Drug Discovery and André Warnecke, Ph.D. as Senior Director of Drug Discovery.
Sign-up for CytRx Establishes Research and Development Team and Opens New Laboratory to Develop Albumin-Binding Anti-Cancer Drug Platform investment picks
2014/1/23
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has initiated a Phase 2 clinical trial to determine preliminary efficacy and safety of aldoxorubicin for HIV-infected patients with Kaposi’s sarcoma (KS). In this open-label Phase 2 clinical trial conducted at the Louisiana State University Health Sciences Center in New Orleans, up to 30 patients in three equal arms will be administered aldoxorubicin at 50, 100 or 150 mg/m2 by 30-minute intravenous infusion.
Sign-up for CytRx Initiates Phase 2 Clinical Trial with Aldoxorubicin for First-Line Treatment of AIDS-Related Kaposi’s Sarcoma investment picks
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced initiation of a Phase 2 clinical trial with the Company’s aldoxorubicin for the treatment of unresectable glioblastoma multiforme (GBM), a deadly form of brain cancer.
Sign-up for CytRx Initiates Phase 2 Clinical Trial with Aldoxorubicin in Patients with Unresectable Glioblastoma Multiforme (Brain Cancer) investment picks
2014/3/24
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has initiated a pivotal global Phase 3 clinical trial to evaluate the efficacy and safety of aldoxorubicin as a second-line treatment for patients with soft tissue sarcoma (STS) under a Special Protocol Assessment with the FDA.
Sign-up for CytRx Initiates Pivotal Global Phase 3 Clinical Trial with Aldoxorubicin for Second-Line Treatment of Soft Tissue Sarcoma investment picks
2014/3/27
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today issued the following statement in response to two recent lawsuits filed in the name of CytRx shareholders: “Our primary corporate objective remains to leverage our Albumin -Binding Anti-Cancer Drug Platform to advance new treatments in cancer care.
Sign-up for CytRx Issues Statement Regarding Recent Lawsuits investment picks
2014/1/21
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received approval from the U.S. Food and Drug Administration (FDA) to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas.
Sign-up for CytRx Receives FDA Approval to Extend Aldoxorubicin Dosing Cycles until Disease Progression in Upcoming Pivotal, Global Phase 3 Trial for Soft Tissue Sarcomas investment picks
2014/3/31
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that aldoxorubicin has received orphan medicinal product designation from the European Commission for the treatment of advanced soft tissue sarcomas.
Sign-up for CytRx Receives Orphan Medicinal Product Designation from the European Commission for Aldoxorubicin in Soft Tissue Sarcoma investment picks
2014/3/5
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the 12 months ended December 31, 2013, and also provided an overview of recent accomplishments and upcoming milestones for its clinical development programs.
Sign-up for CytRx Reports 2013 Financial Results investment picks
2013/8/6
CytRx Corporation (NASDAQ: CYTR) , a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three and six months ended June 30, 2013, and provided a clinical update.
Sign-up for CytRx Reports 2013 Second Quarter Financial Results investment picks
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three and nine-month periods ended September 30, 2013, and provided a clinical update.
Sign-up for CytRx Reports 2013 Third Quarter Financial Results investment picks
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today reported positive results from additional statistical analyses that further support the previously announced highly positive top-line efficacy results from a multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas (STS). Additional analysis determined hazard ratios for the primary endpoint of progression-free survival (PFS) by both investigators at study sites and by a blinded radiology review performed at an independent central laboratory.
Sign-up for CytRx Reports Additional Analyses Supporting Highly Statistically Significant Positive Results from Global Phase 2b Clinical Trial with Aldoxorubicin in Advanced Soft Tissue Sarcomas investment picks
2013/10/31
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announces further positive clinical data from a multi-site global Phase 2b study comparing the Company’s aldoxorubicin as a first-line treatment for advanced soft tissue sarcomas (STS) versus the widely used chemotherapeutic agent doxorubicin.
Sign-up for CytRx Reports Further Positive Interim Data from Global Phase 2b Clinical Trial with Aldoxorubicin versus Doxorubicin as First-Line Therapy in Advanced Soft Tissue Sarcomas investment picks
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced highly positive top-line efficacy results from a multicenter, randomized, open-label global Phase 2b clinical trial.
Sign-up for CytRx Reports Highly Statistically Significant Positive Results from its Global Phase 2b Clinical Trial investment picks
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will issue a news release at 8:00 a.m. Eastern time on Wednesday, December 11, 2013 announcing top-line results of its global Phase 2b clinical trial comparing the company’s aldoxorubicin as a first-line treatment for advanced soft tissue sarcomas (STS) versus the widely used chemotherapeutic agent doxorubicin.
Sign-up for CytRx to Hold Conference Call December 11, 2013 at 10:30 a.m. Eastern Time to Discuss Results of Global Phase 2b Clinical Trial with Aldoxorubicin versus Doxorubicin as First-Line Therapy in Advanced Soft Tissue Sarcomas investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: CytoSorbents Awarded $203K Phase I SBIR Contract from NHLBI/NIH for HemoDefend(TM) to CytRx to Hold Conference Call December 11, 2013 at 10:30 a.m. Eastern Time to Discuss Results of Global Phase 2b Clinical Trial with Aldoxorubicin versus Doxorubicin as First-Line Therapy in Advanced Soft Tissue Sarcomas
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity